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The introduction of antiretroviral therapy (ART) has significantly reduced HIV-associated morbidity
and mortality and has transformed HIV infection into a manageable chronic condition1. However,
strict adherence to daily oral ART remains essential in maintaining viral suppression, preventing the
emergence of resistance and reducing the risk of HIV transmission2,3. Pre-exposure Prophylaxis
(PrEP) has been shown to be effective in the prevention of HIV acquisition in individuals identified as
being at risk of infection4. MVC has particular appeal for use in PrEP5,6. It is readily absorbed into
relevant tissues and has a unique resistance profile compared to other ARVs meaning resistance is
rare7,8. Studies have shown a clear dose-response relationship between protection and adherence9.
The challenges presented by daily oral dosing and the requirement for life-long maintenance of such
dosing has driven interest in the development of Long-Acting Injectables (LAIs), a technology well
established for antipsychotic-therapies and contraception10. Here, we describe the use of emulsion-
templated freeze-drying (ETFD) in the development of oil-blended MVC Solid Drug Nanoparticles
(SDNs) as potential LAI MVC nanomedicines for use in PrEP.
MVC 
Nanodispersion
MVC loading 
(wt.%)
Z-average 
size (nm)
PDI
1 50% 115 0.210
2 50% 160 0.254
3 50% 145 0.213
4 60% 155 0.149
5 60% 170 0.169
6 70% 175 0.165
Table 1. MVC SDNs characterised using dynamic 
light scattering (Malvern Instruments, UK)
SDN Production and Characterisation
An ETFD screen was used to produce and optimise
soybean oil blended solid drug nanosuspensions of
MVC, achieving up to 70 wt.% drug-loading.
Formulations progressed to In vitro release rate
studies are outlined in Table 1.
Dichloromethane-in-water emulsions were prepared
via sonication, consisting of: (i) a 6:1 ratio of MVC
and soybean oil within the dispersed organic phase,
and (ii) combinations of polymers and surfactants
within the aqueous continuous phase. Rapid freezing
and drying of the emulsions gave SDNs dispersed
within a solid matrix of hydrophilic polymer and
surfactant stabilisers, which were subsequently
dispersed in water to yield aqueous nanodispersions
and used for pharmacological assessment.
In vitro MVC Release
Understanding a formulation’s release rate can be used to
predict the rate of drug release from an intramuscular depot.
• MVC release from the 6 formulations and a conventional
MVC preparation (<5% DMSO) was assessed using Rapid
Equilibrium Dialysis (RED) across a size selective
membrane (8 kDa MWCO).
• The results in Fig 1. indicate a, 2.7-, 3.1-, 2.7-, 1.8-, 1.9-
and 1.8-fold reduction in MVC release rate for the SDN
formulations 1 through 6 compared to a conventional
MVC preparation, respectively.
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Figure 1. MVC release rate constant
calculated over 6 h for both conventional
and SDN formulated MVC. RED plates
incubated at 37oC, 100 rpm. (P=<0.001;
unpaired two-tailed t-test).
In vivo LAI Pharmacokinetics
Rats were dosed intramuscularly, into the left hind
leg with 10 mg Kg-1 MVC either as a conventional
MVC preparation (<5% DMSO) or as oil-blended
nanodispersions.
• The results in Fig 2. show MVC was detectable in plasma for up to
7- and 10-days for nanodispersion 1 and 3, respectively.
Nanodispersion 2 displayed comparable exposure with the
conventional MVC dose.
• The parameters outlined in Table 2 show a 3- and 4.9-fold
increase in the AUC0-∞ for nanodispersions 1 and 3, respectively.
• Similarly, a 2.3- and 3.6-fold increase in the terminal half-life (t½)
was observed for nanodispersions 1 and 3, respectively. Whereas
a 1.6-fold decrease in MVC t½ was observed for nanodispersion 2.
• All In vivo work was conducted in accordance with the Animals
(Scientific Procedures) Act 1986 (ASPA), UK Home Office.
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Pharmacokinetic 
parameter
Conventional
MVC
Nanodispersion 
1
Nanodispersion 
2
Nanodispersion 
3
Cmax (ng ml
-1) 71.67 62.88 50.58 69.85
AUC0-∞ (ng.h ml
-1 567.17 1720.51 628.62 2821.3
AUC0-24 (ng.h ml
-1) 244.29 472.19 356.76 714.85
Terminal half-life (t½) 53.23 121.44 33.19 196.04
C24 (ng ml
-1) 3.67 9.30 4.11 7.23
C48 (ng ml
-1) 2.69 7.28 4.08 6.50
C72 (ng ml
-1) 2.66 4.18 2.84 6.32
C168 (ng ml
-1) -* 3.81 -* 4.67
C240 (ng ml
-1) -* -* -* 3.30
(-*)=below limits of quantification
Table 2. Pharmacokinetic parameters derived from Figure 2. 
Figure 2. MVC exposure in adult
male Wistar rats following a single
intramuscular injection of either a
conventional MVC preparation or
each nanodispersion. n=3, ±SD.
• Oil-blended MVC nanodispersions were developed and investigated as LAI formulations.
• Pharmacokinetic studies in rat demonstrate up to 10-days MVC exposure.
• These data support development of a MVC LAI formulation with potential application in PrEP.
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